更正:WT1-mRNA 树突状细胞疫苗接种用于多形性胶质母细胞瘤、恶性胸膜间皮瘤、转移性乳腺癌及其他实体瘤患者:1 型 T 淋巴细胞反应与临床结局相关
Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, an
67.0分
★★★☆☆
ALL SOURCES
Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, an
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other soli
这些数据表明WT1-mRNA/DC疫苗接种在晚期实体瘤患者中是可行的、安全的且具有免疫原性,并显示出临床活性,提示其有潜力帮助改善患者的生存。
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。